The Russian president thought he could outlast the opprobrium of the easily distracted West. It's a gamble he's lost
With few new buyers, the superjumbo's fate is up in the air
Instead of fighting for more regulations, they're pushing for market-based solutions
Vessel wants YouTube stars to focus on another platform
JPMorgan's chief helps kill a Dodd-Frank rule and does the heavy lifting for Wall Street
MetaMind customizes its deep-learning software for businesses that want to learn faster
The final installment of "Serial," a cult-favorite podcast about a murder, will begin just like every other episode—with the name of a prison telecom provider
"These colleges are ranked the top in the country, and it's surprising to me that they can't send out a simple email."
Customer service is one area where small businesses can beat big-box competitors
Founders: Dr. Samir Patel and Dr. David Guyer
VC Investment over the last four quarters: $37.47 million
Founded in 2007, the 15-employee Ophthotech is a biotech company developing treatments for age-related macular degeneration, a common cause of vision loss in older adults. The co-founders' prior venture, Eyetech, was acquired by OSI Pharmaceuticals (OSIP) in 2005 in a deal valued at $900 million.
Key to startup success: "[Our] in-depth understanding of the specific specialty pharma space, coupled with an experienced management and venture investors, has been key to our success."